Omeros (OMER) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Omeros Corporation will announce its Q2 2025 earnings on August 6th, with analysts expecting a loss of ($0.46) per share and revenue of $0.31 million.
• Omeros stock is currently down 4.3%, trading around $3.97, with a market cap of $245.19 million and a 52-week high of $13.60.
• Recent research indicates a mixed sentiment among analysts, with ratings ranging from "sell" to "strong buy," and an average target price of $18.00.

Omeros (NASDAQ:OMER - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Omeros to post earnings of ($0.46) per share and revenue of $0.31 million for the quarter.

Omeros (NASDAQ:OMER - Get Free Report) last issued its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.05). On average, analysts expect Omeros to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Omeros Trading Down 6.7%

NASDAQ:OMER traded down $0.26 during mid-day trading on Friday, hitting $3.61. The stock had a trading volume of 1,863,023 shares, compared to its average volume of 1,351,507. The stock has a 50-day simple moving average of $3.42 and a two-hundred day simple moving average of $6.17. The company has a market capitalization of $222.95 million, a PE ratio of -1.36 and a beta of 2.26. Omeros has a twelve month low of $2.95 and a twelve month high of $13.60.

Hedge Funds Weigh In On Omeros

A hedge fund recently bought a new stake in Omeros stock. Acadian Asset Management LLC bought a new position in Omeros Corporation (NASDAQ:OMER - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 43,695 shares of the biopharmaceutical company's stock, valued at approximately $357,000. Acadian Asset Management LLC owned 0.07% of Omeros at the end of the most recent reporting period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

OMER has been the topic of a number of research reports. D. Boral Capital restated a "buy" rating and set a $36.00 target price on shares of Omeros in a research report on Friday, July 25th. Wall Street Zen lowered shares of Omeros from a "hold" rating to a "sell" rating in a research report on Friday, June 27th. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research report on Friday, May 16th. Finally, HC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Omeros in a research report on Friday, June 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.00.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.